ME 23andMe Holding Co.

23andMe, Inc., a consumer genetics and research company, engages in developing a genetic database to unlock insights leading to the rapid discovery of new targets for drug development. It offers a crowdsourced platform that helps people to access, understand, and benefit from the human genome; access direct-to-consumer genetic testing; and give consumers personalized information about their genetic health risks, ancestry, and traits. The company was incorporated in 2006 and is based in Sunnyvale, California with an additional office in Mountain View, California.

$7.86  +0.21 (2.75%)
As of 12/06/2021 15:59:47 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Diagnostics & Research
Index country:  USA
Country of incorporation:  USA
IPO date:  11/23/2020
Outstanding shares:  93,677,322
Average volume:  2,970,003
Market cap:   $749,418,576
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    90138Q108
ISIN:        US90138Q1085
Valuation   (See tab for details)
PE ratio:   -12.24
PB ratio:   4.72
PS ratio:   6.55
Return on equity:   -8.89%
Net income %:   -51.25%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy